UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2011  SOMAXON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter) Delaware
    
    000-51665
    
    20-0161599(State or other Jurisdiction of Incorporation)
    
    (Commission File Number)
    
    (IRS Employer Identification No.) 3570 Carmel Mountain Road, Suite 100, San Diego, CA
    
    92130(Address of Principal Executive Offices)
    
    (Zip Code) Registrants telephone number, including area code: (858) 876-6500 (Former name or former address if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  1




---



##### 



Item 7.01. Regulation FD Disclosure The information attached as Exhibit 99.1 to this report relating to presentations of data from the clinical
trial program for Somaxon Pharmaceuticals, Inc.s (Somaxon) product Silenor® (doxepin) 3mg and 6mg tablets will be
presented at the Associated Professional Sleep Societies 25th Annual Meeting in Minneapolis, Minnesota on
June 15, 2011 (the Meeting). The information contained in Exhibit 99.1 to this report may also be presented from time
to time by Somaxon at various scientific, investor and analyst meetings after the Meeting. The information in this Current Report on Form 8-K, including the information attached hereto as
Exhibit 99.1, is being furnished pursuant to this Item 7.01 and shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of
that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by
specific reference in such filing to this Current Report on Form 8-K. By filing this Current Report on Form 8-K and furnishing this information, Somaxon makes no admission as to
the materiality of any information in this report. The information contained herein is summary information that is
intended to be considered in the context of Somaxons filings with the SEC and other public announcements that Somaxon
makes, by press release or otherwise, from time to time. Somaxon undertakes no duty or obligation to publicly update or
revise the information contained in this report, although it may do so from time to time as its management believes is
appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press
releases or through other public disclosure. Somaxon cautions you that statements included in this report that are not a description of historical facts
are forward-looking statements. For example, statements regarding the clinical data relating to Silenor, and Somaxons
interpretation of such data, are forward looking statements. The inclusion of forward-looking statements should not be
regarded as a representation by Somaxon that any of its plans will be achieved. Actual results may differ materially
from those set forth in this release due to the risks and uncertainties inherent in Somaxons business, including,
without limitation, inadequate therapeutic efficacy or unexpected adverse side effects relating to Silenor that could
result in recalls or product liability claims; other difficulties or delays in development, testing, manufacturing and
marketing of Silenor; the timing and results of post-approval regulatory requirements for Silenor, and the FDAs
agreement with Somaxons interpretation of such results; the market potential for insomnia treatments, and Somaxons
ability to compete within that market; the scope, validity and duration of patent protection and other intellectual
property rights for Silenor; whether the approved label for Silenor is sufficiently consistent with such patent
protection to provide exclusivity for Silenor; Somaxons ability to successfully commercialize Silenor; Somaxons
ability to successfully enforce its intellectual property rights and defend its patents, including any developments
relating to the recent submission of abbreviated new drug applications for generic versions of Silenor 3 mg and 6 mg
tablets and related patent litigation; the possible introduction of generic competition of Silenor; Somaxons ability
to raise sufficient capital to fund its operations, and the impact of any such financing activity on the level of its
stock price; the impact of any inability to raise sufficient capital to fund ongoing operations, including any patent
infringement litigation; Somaxons ability to operate its business without infringing the intellectual property rights
of others; and other risks detailed in Somaxons periodic filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Somaxon
undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.  2




---



##### 



Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No.
    
    Description99.1
    
    Somaxon Clinical Data Slide Presentation  dated June 15, 2011
  3




---



##### 



SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized. SOMAXON PHARMACEUTICALS, INC.Date: June 15, 2011By:
    
    /s/ Matthew W. OnaitisName:
    
    Matthew W. OnaitisTitle:
    
    Senior Vice President and General Counsel
   4




---



##### 



EXHIBIT INDEX Exhibit No.
    
    Description99.1
    
    Somaxon Clinical Data Slide Presentation  dated June 15, 2011
  5